Blog

Changing the treatment landscape for patients with resistant melanoma – Danish Cancer Institute

Loulieta Nazerai/LinkedIn

Mar 19, 2025, 12:03

Changing the treatment landscape for patients with resistant melanoma – Danish Cancer Institute

Danish Cancer Institute posted on LinkedIn about recent paper by Loulieta Nazerai et al., titled “Thiopurine therapy enhances immune checkpoint inhibitor efficacy in low-mutational burden melanoma: A promising anticancer approach” published on PNAS.

Authors: Loulieta Nazerai, Christina Tsiavou, Lina Vardouli, Kjeld Schmiegelow, and Daniela De Zio

Changing the treatment landscape for patients with resistant melanoma - Danish Cancer Institute

“‘I hope my research will improve the options for patients who don’t have many options at the moment.’

Meet Loulieta Nazerai, Postdoc in the Melanoma Research Team led by Daniela De Zio.

Loulieta specialises in cancer immunotherapy, and recently her research led to an important discovery that could change the treatment landscape for patients with resistant melanoma.”

Video attached to the post.

cancer cancer immunotherapy Christina Tsiavou Daniela De Zio Danish Cancer Institute Kjeld Schmiegelow Lina Vardouli Loulieta Nazerai Melanoma OncoDaily Oncology

Oncologist Near Me - Douglas Flora: Pioneering AI Integration in Cancer Care

Douglas Hanahan was Honored with the 2025 Pezcoller Foundation-AACR International Award for Extraordinary Cancer Research

Bente Mikkelsen Appointed as Director of Global Engagement Strategies at St. Jude Children's Research Hospital

Audrey Evans - mother of neuroblastoma, a force for good in the world

New Paper Alert: Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer